GLP-1 Access and Obesity Care Pathways in Poland

Obesity represents a chronic, progressive metabolic disease requiring structured clinical interventions rather than reliance on short-term behavioral modifications alone [1]. In contemporary clinical practice, the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists has transformed the therapeutic landscape by offering potent glycemic control and substantial body mass reduction [1], [8]. Within European healthcare systems, establishing coherent care pathways is crucial to mitigating chronic noncommunicable diseases and cardiovascular risks [8].

Despite widespread clinical endorsement, access to incretin-based therapies across Central and Eastern Europe faces structural and economic constraints [1]. In Poland, reimbursement policies, supply variability, and fragmented coordination between primary care physicians and bariatric specialists hinder equitable access [1], [6]. Furthermore, integrating pharmacotherapy into broader multidisciplinary pathways requires careful sequencing alongside surgical interventions and lifestyle support to prevent weight regain and optimize long-term health outcomes [5], [6].

Clinical integration also presents distinct procedural challenges, particularly regarding the delayed gastric emptying caused by GLP-1 receptor agonists in surgical candidates [3], [8]. Managing patients who receive pharmacotherapy prior to elective or metabolic operations requires revised perioperative anaesthetic protocols and objective gastric assessment techniques such as point-of-care ultrasound [3]. Clarifying these interaction points within standardized clinical protocols is vital for institutional safety and multidisciplinary operational efficiency across surgical wards [7], [8].

This study evaluates the systemic factors governing GLP-1 access and the structuring of comprehensive obesity care pathways in Poland. Utilizing a rigorous desk-based synthesis of clinical trials, national healthcare guidelines, and comparative pharmacoeconomic studies, this work analyzes outpatient referral mechanisms, perioperative safeguards, and combined pharmacological-surgical models [1], [6], [7]. The resulting framework outlines policy adaptations and clinical pathway refinements necessary to enhance treatment sustainability, safety, and healthcare delivery across the Polish public and private health sectors.